Skip to main content

Table 2 Results of sensitivity analysis

From: The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis

Excluded study

Original OR and 95%CI

After excluding study

  
  

OR and 95%CI

I2

PQ值

Ruiter 2012

0.73 (0.66–0.80)

0.83 (0.68–1.01)

87.8%

0.000

Bodmer 2011

0.83 (0.57–1.21)

0.82 (0.69–0.98)

88.9%

0.000

Sung 2020

0.51 (0.36–0.72)

0.84 (0.71–1.01)

88.4%

0.000

Zhao 2022

1.01 (0.51–1.98)

0.82 (0.68–0.98)

88.9%

0.000

Valente 2017

1.35 (0.68–2.66)

0.83 (0.68–1.01)

88.8%

0.000

Oh 2020

0.88 (0.70–1.11)

0.82 (0.68–0.98)

88.9%

0.000

Murff 2018

0.85 (0.57–1.27)

0.82 (0.68–0.98)

88.9%

0.000

Tsilidis 2014

0.70 (0.45–1.07)

0.83 (0.69–0.99)

88.9%

0.000

Wang 2013

1.14 (0.68–1.91)

0.81 (0.68–0.97)

88.9%

0.000

Liao 2012

0.85 (0.39–1.89)

0.82 (0.69–0.98)

88.9%

0.000

Oliveria 2008

1.26 (0.80–1.99)

0.81 (0.67–0.96)

88.8%

0.000

Tseng 2018

0.49 (0.25–0.96)

0.84 (0.70–1.00)

88.8%

0.000

Currie 2009

0.16 (0.10–0.27)

0.88 (0.75–1.04)

85.7%

0.000

De 2017

1.11 (0.72–1.71)

0.81 (0.68–0.97)

88.9%

0.000

Farmer 2019

3.11 (1.24–7.76)

0.80 (0.67–0.95)

88.5%

0.000

Lee 2018

0.86 (0.77–0.96)

0.82 (0.67–1.00)

88.9%

0.000

Lee 2011

0.15 (0.03–0.79)

0.84 (0.70–1.00)

88.7%

0.000

Lu 2015

1.50 (1.07–2.09)

0.80 (0.67–0.95)

88.3%

0.000

Vicentini 2018

1.51 (0.59–3.89)

0.81 (0.68–0.97)

88.9%

0.000

Walker 2015

1.01 (0.61–1.68)

0.81 (0.68–0.98)

88.9%

0.000

You 2020

1.34 (1.21–1.48)

0.79 (0.68–0.93)

79.8%

0.000

Hsieh 2012

0.63 (0.28–1.41)

0.83 (0.69–0.99)

88.9%

0.000

Van 2011

0.64 (0.56–0.74)

0.83 (0.70–1.00)

87.6%

0.000

Li 2009

0.38 (0.22–0.69)

0.85 (0.71–1.01)

88.4%

0.000

Sung 2020

Currie 2009

Hsieh 2012

Van 2011

NA

0.95(0.80–1.12)

83.7%

0.000